Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Phase 1

Completed

Conditions: Lung Cancer
Advanced Non-small Cell Lung Cancer
KRAS Gene Mutation

Interventions: Drug: Binimetinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-11-16

Last Posted Date: 2021-07-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 18

Registration Number: NCT02964689

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 1 locations

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Phase 1

Completed

Conditions: Neoplasms

Interventions: Biological: vibostolimab
Biological: pembrolizumab/vibostolimab coformulation
Biological: pembrolizumab
Drug: pemetrexed
Drug: carboplatin
Drug: cisplatin
Drug: etoposide

First Posted Date: 2016-11-15

Last Posted Date: 2024-08-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 470

Registration Number: NCT02964013

Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Radiation: hypofractionated radiotherapy
Drug: Pemetrexed
Drug: Etoposide

First Posted Date: 2016-10-27

Last Posted Date: 2017-11-30

Lead Sponsor: The Netherlands Cancer Institute

Registration Number: NCT02947113

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: nivolumab
Drug: paclitaxel
Drug: veliparib
Drug: carboplatin

First Posted Date: 2016-10-25

Last Posted Date: 2019-10-23

Lead Sponsor: AbbVie

Target Recruit Count: 25

Registration Number: NCT02944396

Locations: 🇺🇸
University of Chicago /ID# 153824, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center /ID# 153821, Durham, North Carolina, United States
🇺🇸
University of Alabama at Birmingham - Main /ID# 155135, Birmingham, Alabama, United States

and more 3 locations

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Phase 1

Active, not recruiting

Conditions: Endometrial Cancer
Endometrial Cancer Recurrent
Lung Cancer Recurrent
Lung Cancer
Non-small Cell Lung Cancer Metastatic
Non-small Cell Carcinoma

Interventions: Drug: RGX-104
Drug: Docetaxel
Drug: Pembrolizumab
Drug: Ipilimumab
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2016-10-04

Last Posted Date: 2024-10-24

Lead Sponsor: Inspirna, Inc.

Target Recruit Count: 146

Registration Number: NCT02922764

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States

and more 18 locations

Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

Phase 1

Completed

Conditions: Salivary Gland Tumors
Head and Neck Cancer

Interventions: Radiation: Intensity-modulated radiotherapy
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-10-03

Last Posted Date: 2018-03-20

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 20

Registration Number: NCT02921984

Locations: 🇨🇳
Shanghai ninth people's hospital, Shanghai, Shanghai, China

Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Secondary
Advanced Stage IIIB
High Thymidylate Synthase Expression

Interventions: Drug: Oral vinorelbine
Drug: Pemetrexed
Drug: Cisplatin
Drug: Maintenance with Metronomic Oral Vinorelbine
Drug: Maintenance with Pemetrexed

First Posted Date: 2016-09-29

Last Posted Date: 2018-01-16

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 2

Registration Number: NCT02919462

Locations: 🇮🇹
U.O. Oncologia Medica, Faenza, RA, Italy
🇮🇹
U.O. Oncologia Ospedale degli Infermi, Rimini, Italy
🇮🇹
Ircc Irst, Meldola, FC, Italy

and more 2 locations

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Phase 3

Completed

Conditions: Mesothelioma

Interventions: Biological: Nivolumab
Drug: Pemetrexed
Biological: Ipilimumab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2016-09-14

Last Posted Date: 2024-05-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 605

Registration Number: NCT02899299

Locations: 🇺🇸
Local Institution - 0014, New Haven, Connecticut, United States
🇺🇸
Local Institution - 0013, Detroit, Michigan, United States
🇺🇸
Local Institution - 0004, Rochester, Minnesota, United States

and more 104 locations